Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION long-term follow-up of delandistrogene moxeparvovec in Duchenne muscular dystrophy
2023-505043-39-00Phase 3Authorised
- Sponsor
- Sarepta Therapeutics
- Start
- Mar 2024
- Modality
- Gene Therapies
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoint: Number of participants with treatment-emergent adverse events, serious adverse events, and adverse events of special interest. Planned start Mar 2024; status: authorised.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2023-505043-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505043-39-00.